Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

SenoRx announced a poster presentation on interim results of the first 100 patients in its Contura MLB registry study delivered at the ASTRO

SenoRx (Nasdaq:SENO) announced that a poster presentation summarizing clinical findings of the first 100 patients in its Contura Multi-Lumen Balloon (MLB) registry study was delivered at the Annual Meeting of the American Society for Therapeutic Radiology and Oncology ( ASTRO ) on November 3, 2009 in Chicago, Illinois.

The study, titled "Initial Dosimetric Experience: Contura Multi-Lumen Balloon (MLB) Registry Trial," is designed to compare the dosimetric efficacy of Contura MLB with a single central lumen balloon device and to quantify the dosimetric improvement of multi-lumen use over single-lumen use. The Principal Investigators of the study are Drs. Frank A. Vicini, Douglas W. Arthur, Dorin Todor and Thomas B. Julian. Based on the first 100 patients, the authors preliminarily confirmed that without the dosimetric optimizing capabilities, the safe use of a single-lumen balloon is limited to patients with ideal cavity geometry and balloon symmetry. This initial data shows that the use of multiple, offset lumens allow the optimization of target coverage while minimizing dose to nearby skin and chest wall, thus creating a new improved dosimetric standard.

"We are gratified that these interim results of our registry study continue to provide preliminary confirmation of our expectations for the benefits of the multi-lumen design of our Contura MLB," said Lloyd Malchow, SenoRx President and Chief Executive Officer. "This study and others are helpful in supporting our clinical education programs for Contura MLB. We are also pleased that over 30 sites are participating in our Contura MLB Registry Study in which 227 patients have now enrolled."

Source: SenoRx

You can discuss about SenoRx and its products & services in the SenoRx Company User Group